SCLX
Scilex Holding Co
NASDAQ · Pharmaceuticals
$8.49
+0.63 (+8.02%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.62M | 16.86M | 18.16M |
| Net Income | 3.41M | 3.00M | 3.07M |
| EPS | — | — | — |
| Profit Margin | 20.5% | 17.8% | 16.9% |
| Rev Growth | -3.0% | +5.1% | -1.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 9.29M | 11.67M | 10.30M |
| Total Equity | 42.87M | 39.45M | 37.80M |
| D/E Ratio | 0.22 | 0.30 | 0.27 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.17M | 6.50M | 7.12M |
| Free Cash Flow | 2.59M | 2.15M | 2.89M |